Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Cancer immunotherapy, which leverages features of the immune system to target neoplastic
cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly …

Immune checkpoint inhibitors (ICIs) are now FDA-approved for the treatment of 8 different
cancers, and more approvals are likely, including use of these drugs in combinations …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune checkpoint inhibitors (ICIs) have now been approved in numerous and diverse
cancer types and combination regimens. Effective recognition and treatment of ICI toxicities …

Abstract Immune-related Adverse Events (irAEs) are the most significant toxicities
associated with the use of checkpoint inhibitors, and result from disinhibition of the host's …

Purpose of review Immune checkpoint inhibitors have revolutionised the treatment of
multiple malignancies and have a growing list of indications. As our familiarity with these …

Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm
across a broad spectrum of malignancies. This new class of agents also challenges …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several
cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 …